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Background: Despite Australia’s sunny climate, low vitamin D levels are increasingly prevalent. Sun exposure is
limited by long working hours, an increase in time spent indoors, and sun protection practices, and there is
limited dietary vitamin D fortification. While the importance of vitamin D for bone mineralization is well known,
its role as a protective agent against chronic diseases, such as type 2 diabetes and cardiovascular disease, is less
understood. Observational and limited intervention studies suggest that vitamin D might improve insulin
sensitivity and secretion, mainly via its anti-inflammatory properties, thereby decreasing the risk of development
and progression of type 2 diabetes. The primary aim of this trial is to investigate whether improved plasma
concentrations of 25-hydroxyvitamin D (25(OH)D), obtained through vitamin D supplementation, will increase
insulin sensitivity and insulin secretion. A secondary aim is to determine whether these relationships are mediated by a
reduction in underlying subclinical inflammation associated with obesity.
Methods/Design: Fifty overweight but otherwise healthy nondiabetic adults between 18 and 60 years old, with low
vitamin D levels (25(OH)D < 50 nmol/l), will be randomly assigned to intervention or placebo. At baseline, participants
will undergo a medical review and anthropometric measurements, including dual X-ray absorptiometry, an intravenous
glucose tolerance test, muscle and fat biopsies, a hyperinsulinemic euglycemic clamp, and questionnaires assessing
diet, physical activity, sun exposure, back and knee pain, and depression. The intervention group will receive a first dose
of 100,000 IU followed by 4,000 IU vitamin D (cholecalciferol) daily, while the placebo group will receive apparently
identical capsules, both for a period of 16 weeks. All measurements will be repeated at follow-up, with the primary
outcome measure expressed as a change from baseline in insulin sensitivity and secretion for the intervention group
compared with the placebo group. Secondary outcome measures will compare changes in anthropometry,
cardiovascular risk factors, and inflammatory markers.
Discussion: The trial will provide much needed clinical evidence on the impact of vitamin D supplementation on
insulin resistance and secretion and its underlying mechanisms, which are relevant for the prevention and management
of type 2 diabetes.
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Vitamin D has well established endocrine functions in
calcium absorption and healthy mineralization of bone
as well as muscle function [1]. Low vitamin D levels
have also been associated with many chronic diseases,
including obesity [2], type 2 diabetes [3], cardiovascu-
lar disease [4], and cardiovascular and all-cause mor-
tality [5]. However, knowledge gaps around vitamin D
in these chronic diseases remain significant. This is
increasingly clinically relevant today with vitamin D
deficiency being prevalent worldwide as people adopt
sedentary indoor lifestyles and use sunscreen and pro-
tective clothing to reduce the risk of skin cancer [1].
Diet is also not an ideal way to obtain vitamin D be-
cause few foods are naturally high in vitamin D and
foods fortified with vitamin D are limited internation-
ally [1]. The use of supplements offers a practical op-
tion for treating deficiency, while avoiding conflict
with current public health measures for sun avoidance
to protect against skin cancer [6]. However, the level of
supplementation appropriate to improve vitamin D
status remains controversial [7]. Currently, recom-
mended daily oral intake is between 5 and 15 μg/day
(200–600 IU/day) for adults (ages 19–70) [8, 9]. How-
ever, several recent studies suggested that an oral in-
take of at least 100 μg/day (4,000 IU/day) is required
to raise serum concentrations of 25(OH)D to an opti-
mal level within 2 to 3 months [10, 11]. Yet few exist-
ing studies have reached this level of replacement.
In relation to type 2 diabetes and cardiovascular risk
factors, cross-sectional studies have shown that low
plasma concentrations of 25(OH)D are associated with
higher fasting serum glucose concentrations [12]; in-
creased insulin resistance [13]; increased first and sec-
ond phase insulin secretion [14, 15]; higher levels of
haemoglobin A1c (HbA1c) [16, 17]; higher blood pres-
sure [18, 19]; and higher levels of triglycerides and lower
high-density lipoprotein cholesterol [20]. Prospectively,
low serum concentrations of 25(OH)D have been associ-
ated with the development of insulin resistance [21],
type 2 diabetes [22], hypertension [23], incidence of car-
diovascular disease, and mortality [23–25]. Despite epi-
demiological data, there are relatively few good-quality
interventional studies. Recent meta-analyses show sig-
nificant heterogeneity in study quality, risk of bias,
duration, dosages, and vitamin D deficiency status of
participants, sample sizes, as well as surrogate measures
of diabetes and cardiovascular disease, making it difficult
to interpret study findings [23, 26]. In addition, many
studies did not account for lifestyle factors, nor have they
included dietary intake of vitamin D or calcium in their
analyses, all of which affect both vitamin D levels and risk
of type 2 diabetes and cardiovascular disease [23]. While
recent evidence is limited and inconclusive, it does suggestthat vitamin D might only have beneficial effects on vita-
min D deficient individuals (25(OH)D < 50 nmol/l) who
have received supplementation of sufficient dosages and
durations, factors which require consideration in the de-
sign and execution of future trials.
Chronic low-grade inflammation is another factor that
occurs in obesity. It is a risk factor for insulin resistance
and many chronic diseases including type 2 diabetes and
cardiovascular disease [27, 28]. There is evidence from
in-vitro studies that vitamin D has anti-inflammatory
properties [29–31]. However, there is a lack of human
data [29].
While some large-scale trials are currently underway
to assess the relationship between vitamin D and cardio-
vascular risk or disease [32], the role of vitamin D in
insulin resistance or secretion and in regulating under-
lying chronic inflammation still needs to be assessed
with good-quality trials and using gold-standard mea-
sures of glucose metabolism to address existing know-
ledge gaps [33].
To this end, we aim to perform a well-designed ran-
domized placebo-controlled trial in healthy but over-
weight and obese individuals, as they are, on average,
insulin resistant and have chronic low-grade inflamma-
tion. We aim to measure insulin sensitivity and secretion
using gold-standard methodology, rather than examining
glucose levels, HbA1c or using indirect measures of in-
sulin sensitivity or secretion, which tend to change
only slightly in nondiabetic individuals [23]. We will
also measure blood pressure and lipid profile as surro-
gate measures of cardiovascular risk. Finally, chronic
low-grade inflammation will be explored as a mechanism
potentially linking low vitamin D levels and insulin sensi-
tivity or secretion as well as cardiovascular risk factors.
Methods/Design
Study design and setting
This study is a parallel-group randomized placebo-
controlled trial. The study design is presented in Fig. 1.
Fifty overweight but otherwise healthy normoglycaemic
adults aged between 18 and 60 years, and with serum
concentrations of 25(OH)D between 25 and 50 nmol/l
on screening will be enrolled. Participants will be ran-
domized to receive either placebo or vitamin D supple-
mentation (25 participants in each arm) for 16 weeks,
with a goal of achieving optimal 25(OH)D levels of ap-
proximately 100 nmol/l. Those with severe deficiency
(serum 25(OH)D levels below 25 nmol/l) will not be in-
cluded in the current trial but will be allocated to a
nonrandomized mandatory treatment group and stud-
ied before and after supplementation. Overweight and
obese subjects will be selected for this study, as they
are generally more insulin resistant and more seden-
tary, and have higher levels of inflammatory markers
Fig. 1 Trial protocol. DEXA, dual X-ray absorptiometry; FBC, full blood count; IVGTT, intravenous glucose tolerance test; LFT, liver function test;
OGTT, oral glucose tolerance test; UEC, urea, electrolytes, creatinine
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that increase the risk of type 2 diabetes [34, 35]. Partic-
ipants will be sought out via several advertising strat-
egies, including posters, flyers, newspapers, and email
newsletters at Monash University and Monash Medical
Centre in Melbourne, Australia, and via online adver-
tising avenues, including social media and popular
community websites. Interested participants will be in-
formed that their participation is voluntary and that
they can withdraw at any time, and they will also be asked
to read the details of the study provided in an information
pack. Once all concerns and questions have been ad-
dressed, participants will be asked to sign an informed
consent form prior to commencing any tests.Inclusion criteria
To take part in the trial, participants must be within the
age range of 18 to 60 years inclusive, nondiabetic, and
generally healthy, as determined by medical screening.
Eligible participants must be overweight or obese (body
mass index > 25 kg/m2). Their weight should not exceed
159 kg, owing to facility restrictions, and it should be
stable, with a change of less than 5 kg in the preceding
year. They should also have no intention to lose weight
or change their diet or physical activity during the trial.
To be included, individuals should also have a serum con-
centration of 25(OH)D of <50 nmol/l. However, those
with frank vitamin D deficiency (<25 nmol/l) will not be
randomized, but will instead be purposely allocated to the
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might not be safe for these individuals.
Exclusion criteria
Exclusion criteria will include smoking, high alcohol use
(more than four standard drinks per week for men and
more than two standard drinks per week for women),
hypercalcemia, allergies, diabetes (previously diagnosed
or on the basis of an oral glucose tolerance test), and the
use of medication, including vitamins and other supple-
ments. Based on medical history or physical or laboratory
examination, participants will also be excluded if they have
any kidney, cardiovascular, hematological, respiratory,
gastrointestinal, endocrine or central nervous system dis-
eases, as well as psychiatric disorders, active cancer within
the preceding 5 years, or the presence of acute inflamma-
tion. Women who are experiencing menopause, pregnant,
or lactating will also be excluded.
Sample size calculation
Based on data from a similar healthy cohort of overweight
or obese subjects in our metabolic laboratory, with a mean
(standard deviation) insulin-mediated glucose uptake value
of 8.1 (2.0) mg glucose per kg per minute, a sample size of
25 completing each arm is required to detect a 20 %
change in insulin-mediated glucose uptake between treat-
ment group and placebo. The 20 % increase is based onFig. 2 Study timeline. IVGTT, intravenous glucose tolerance test; OGTT, oralresults from a study indicating the effect of vitamin D sup-
plementation in subjects with diabetes using a comparable
insulin sensitivity measurement technique and 4 weeks’
treatment [36]. Based on a type I error of 0.05 (two-tail)
and a type II error of 0.20 (power = 80 %), we would re-
quire 50 participants to complete the trial.Screening
The study timeline is presented in Fig. 2. Female partici-
pants who are not taking contraceptives will be required
to commence metabolic testing in the follicular phase
and a urine pregnancy test will be performed to exclude
pregnancy. At visit 1, a signed informed consent form
will be obtained from each participant followed by
screening by a registered medical practitioner, who will
collect medical history and perform a physical examin-
ation, including measurement of blood pressure, height,
body weight, and waist and hip circumference.
At the second visit, participants will undergo an oral
glucose tolerance test with measurement of fasting and
2 hour glucose levels to exclude diabetes according to
World Health Organization guidelines [37]. Blood sam-
ples will be sent to Monash Pathology services to be an-
alyzed for serum concentration of 25(OH)D as well as
full blood count, kidney and liver function tests, lipid
profile, parathyroid hormone levels, and concentrationglucose tolerance test
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tein (CRP) as a marker of inflammation.
Baseline assessment
Baseline assessments will commence at the third visit,
which will involve a muscle biopsy from the vastus
lateralis, adipose tissue biopsies from subcutaneous ab-
dominal tissue, and body composition assessment by
dual X-ray absorptiometry (Monash Medical Centre
Radiology Department). The final baseline visit will in-
volve an intravenous glucose tolerance test and a hyperin-
sulinemic euglycemic clamp. Participants will complete
validated questionnaires to assess self-reported sun ex-
posure habits, physical activity (International Physical
Activity Questionnaire) [38], knee and back pain, de-
pression (Beck’s Depression Inventory) [39], and diet
(3-day food record).
Randomization
Following successful screening and baseline assess-
ment, subjects will be randomized by a computerized
randomization program to commence treatment with
either vitamin D or placebo. This randomization will
be done in blocks of four by sex and time of study
entry (seasons) to ensure balance between the sexes in
each test group and to control for the effect of sea-
sonal change. Randomization of participants to the
intervention or placebo groups will be completed by a
researcher within our department (Monash Centre for
Health Research and Implementation) who is not involved
in the trial data collection, analysis, or reporting. This
researcher will receive packaged supplements, produced
by a clinical trials pharmacy, at Alfred Hospital. Capsules
of vitamin D and placebo will be provided in clear con-
tainers and they will be identical and tasteless, to ensure
that both participants and investigators are blinded to the
treatment. To maximize compliance, participants will be
provided with a calendar sheet highlighting the study
period, so they can cross out each day as they go, and re-
turn the sheet along with the empty containers at the end
of the study.
Intervention
Following randomization, each participant will be
given an initial first dose of 2,500 μg (100,000 IU) of
vitamin D or an equivalent number of placebo tablets
to be taken orally in front of researchers in the clinic.
For those in the intervention group, this first dose is ex-
pected to elevate their serum concentration of 25(OH)D
to 100 nmol/l within one week [10]. After the first dose,
participants will take 100 μg/day (4,000 IU, four tablets) of
vitamin D daily to keep their serum concentration of
25(OH)D at an optimal level. The daily dose selected
is based on the amount required for repletion within a3-month period [11], and is well below levels of intake
associated with toxicity [40]. Participants on placebo
will take four tablets daily of identical appearance. All par-
ticipants will be instructed to consume four tablets daily,
and otherwise maintain their usual daily activities.
Follow-up visits
Participants will be scheduled for their follow-up visits
during the last week of their treatment intake. All proce-
dures performed during baseline assessment including
blood pressure measurement, anthropometry, percutan-
eous muscle and adipose tissue biopsies, intravenous
glucose tolerance testing, and glucose clamp will be re-
peated, except for the oral glucose tolerance test, as this
is only performed initially to screen for diabetes. Partici-
pants will again be asked to fill out the same question-
naires and another 3-day food diary.
Safety considerations
During the screening, baseline, and follow-up proce-
dures, any medical conditions or abnormalities detected
(except vitamin D status) will be promptly discussed
with the participant by a qualified medical practitioner
involved in the study. Where applicable, participants will
be treated, referred, or advised to visit their general prac-
titioner for follow-up. Individuals with frank vitamin D
deficiency (<25 nmol/l) will not be included in the trial,
as not treating these individuals would be unethical;
hence, immediate treatment with vitamin D takes prece-
dence. This severely deficient group will receive the
same vitamin D supplementation and protocol (except
randomization), and, along with their investigators, will
remain blinded to maintain allocation concealment for
this group. Results from these individuals will be ana-
lyzed separately from the trial. All participants will be
informed of their screening blood test results after they
have completed participation in the study, and they will
be advised to visit their general practitioner to discuss
strategies to increase or maintain their vitamin D levels,
as well as improve their diabetes and cardiovascular
risk profile.
Ethics
This trial has received ethical approval from the Monash
University Human Research Ethics Committee and
Monash Health (protocol ID: CF13/3874 – 2013001988).
Outcome measurements
The primary outcome measure in this trial is the differ-
ence (change) in insulin sensitivity between the vitamin
D and placebo groups. Secondary outcome measures in-
clude changes in insulin secretion, weight, body mass
index, waist, waist to hip ratio, resting systolic and
diastolic blood pressure, lipid profile, and markers of
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CRP, TNFα, macrophage migration inhibitory factor,
monocyte chemotactic protein-1, and NFκB activity.
Measurement of insulin signaling in skeletal muscle
and gene expression of inflammatory markers in adi-
pose tissue will also be included as secondary outcome
measures. Other outcome measures will include self-
reported questionnaire data and nutrient analyses de-
rived from dietary records.
Data collection and analysis
Anthropometry
Body mass index Using a digital scale (Tanita BWB-600,
Australia) and stable stadiometer (Seca 206, Australia),
body weight (kg) and height (m) will be measured, both at
baseline and following the intervention period, during
which participants will be lightly clothed and without
shoes. These measurements will be converted to body
mass index using the formula:
Body mass index ¼ Weight kgð Þ = Height mð Þ2:
Waist to hip ratio Central adiposity will be assessed
in duplicate using a constant-tension tape for measur-
ing waist and hip circumference. Waist circumference
will be measured by a single experienced researcher at
the midpoint between the upper iliac crest and the
lowermost rib at the end of a normal expiration, while
hip circumference will be determined at around the
widest part of the buttocks. Waist to hip ratio will be
calculated using the formula:
Waist to hip ratio ¼ Waist circumference cmð Þ = Hip circumference cmð Þ:
Body fat composition (dual X-ray absorptiometry)
Dual energy X-ray absorptiometry will be used to meas-
ure whole body fat composition. The fat tissue mass
measured in this way consists of the sum of the fatty ele-
ments of all the soft tissue, not just adipose tissue, while
the lean tissue mass reflects the sum of all chemical fat-
free tissue components. Dual X-ray absorptiometry has
been validated as an accurate, safe, and noninvasive
method of measuring soft tissue body composition by
region [41].
Metabolic measures
Oral glucose tolerance test After a 10–12 hour over-
night fast, participants will ingest 75 g of glucose over
2 min. Blood samples will be drawn at 0 and 120 mi-
nutes to analyze plasma glucose levels and determine
diabetes status.Percutaneous muscle and adipose tissue biopsy Ap-
proximately 120 mg of skeletal muscle (vastus lateralis
muscle) will be obtained by percutaneous muscle biopsy
under local anaesthetic, immediately frozen and stored
at −80 °C for later analysis. Adipose tissue (approxi-
mately 10 g) will be obtained by needle biopsy from the
abdominal area, also under local anaesthetic, and will
be immediately frozen and stored at −80 °C for later
analysis.
Hyperinsulinemic euglycemic clamp A euglycemic glu-
cose clamp will be used to measure insulin sensitivity.
After collecting baseline blood and plasma glucose levels
at 0 min, the clamp will be initiated by an intravenous
bolus injection of insulin (9 mU/kg). Insulin will then be
constantly infused at a rate of 40 mU/(m2 min) for ap-
proximately 120 min into an arm vein, while glucose is
variably infused to maintain euglycemia. Plasma glucose
values will be monitored every 5 minutes during the
clamp and the variable infusion rate of glucose will be
adjusted to maintain blood glucose at a constant value
of 5 mmol/l for at least 30 minutes.
Intravenous glucose tolerance test Acute insulin secre
tory response will be measured using an intravenous glu-
cose tolerance test. First, baseline blood will be collected
at −10 and 0 min, after which 50 ml of 50 % glucose will
be delivered intravenously over a 3 min period. Blood
will then be collected for insulin concentration meas-
urement at 3, 4, 5, 6, 8, 10, 15, 20, 25, and 30 min and
glucose concentrations will be analyzed at each of these
times, to determine insulin secretory response. This
will be calculated as the average incremental plasma in-
sulin level from the third to the fifth minute after the
glucose bolus.
Cardiovascular measures
Blood pressure Resting systolic and diastolic blood pres-
sure and pulse rate will be measured using an automated
oscillometric measurement system (Omron, Australia)
after a 20-min rest. The average blood pressure derived
from three measurements will be recorded.
Lipid profile Lipid profile-related parameters to be
measured include plasma total cholesterol, triglycer-
ides, low-density and high-density lipoprotein choles-
terol using a standard commercial enzymatic assay, a
Beckman Coulter LX20PRO analyzer and SYNCHRON
Systems lipid and multi calibrators (Beckman Coulter
Diagnostics, Australia).
Inflammatory measures
Inflammatory markers Plasma inflammatory markers
(IL-1β, IL-6, IL-8 and IL-10, TNFα, macrophage migration
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will be measured using a commercial automated chemi-
luminescent enzyme immunoassay analyzer (Immulite,
Diagnostic Products Corporation, CA, USA), while
plasma CRP will be analyzed via highly sensitive near
infrared particle immunoassay rate methodology and a
Beckman Coulter SYNCHRON LX system chemistry
analyzer (Beckman Coulter Inc., Australia).
NFκB and Jun N-terminal protein kinase-1 activity
Nuclear extracts of white blood cells will be obtained and
analyzed for the p50/p65 subunit of NFκB for their bind-
ing capacity for an NFκB consensus sequence (Active
Motif, CA, USA). The bound subunits are sequentially
incubated with specific antibodies to either the p50 or p65
subunit and then detected by their supershift on gel elec-
trophoresis (Perkin Elmer, MA, USA). Activation of Jun
N-terminal protein kinase-1 in the muscle and adipose
tissue will be detected by immunochemistry and Western
blotting, using antibodies from Cell Signaling Technology
(MA, USA) and quantified using Quantity One imaging
software (Bio-Rad Laboratories Inc., CA, USA).
Insulin signaling
We will measure changes in the expression and activa-
tion of important insulin signaling proteins, including
the insulin receptor, insulin receptor substrate (IRS)-1
and 2, p85 subunit of phosphatidylinositol 3-kinase, and
PKB/Akt, using Western blotting analysis, immunopre-
cipitation techniques, and commercially available phos-
phospecific antibodies (Santa Cruz Biotechnology, USA;
Upstate Biotechnology, USA; Cell Signaling, MA, USA).
Gene expression
Gene expression of TNFα, IL-6, CRP, NFκB, and IKKβ
in muscle and adipose tissue will be determined by real-
time quantitative RT-PCR using the TaqMan system,
based on real-time detection of accumulated fluores-
cence (ABI Prism 7700 sequence detection system; PE
Biosystems, CA, USA). The protein concentration of all
protein isolates will be determined using the bicinchoni-
nic acid protein assay (Pierce Biotechnology Inc., IL,
USA), according to the manufacturer’s instructions.
Other blood and tissue analyses
Other analyses include measurement of 25(OH)D con-
centration by direct competitive chemiluminescent im-
munoassay and a DiaSorin LIAISON Analyzer (DiaSorin
Inc., USA) (CV 15 %); measurement of intact parathy-
roid hormone levels by an Access/DXI PTH assay, which
is a paramagnetic particle chemiluminescent immuno-
assay for quantitative analysis (Beckman Coulter Inc.,
Australia); and measurement of insulin levels by Access/
DXI ultrasensitive insulin assay, which is a simultaneousone-step immuno-enzymatic sandwich assay with CV
levels of 7 %, 6.2 %, and 4.6 %, respectively (Beckman
Coulter Inc., Australia). Serum concentrations of calcium,
magnesium, and phosphate will be determined using auto-
mated colorimetric assays carried out on SYNCHRON LX
and SYNCHRON DXC800® systems (Beckman Coulter
Diagnostics, Australia), while plasma concentration of glu-
cose will be determined using the SYNCHRON DXC800
and by an oxygen consumption rate method using a glu-
cose oxygen electrode (Beckman Coulter Inc., Australia).
Self-reported measures
Nutrient analysis Because some diets might be richer
in vitamin D content than others, it was considered im-
portant to assess dietary practices of the study partici-
pants. The participants will be asked not to change their
dietary habits during the study, and to complete a 3-day
food diary, which will provide a snapshot of the types of
food consumed by the participants when they entered the
study as well as at follow-up, to ensure no major change
in diet. These 3-day records will be analyzed with Food
Works Professional 2007 (Xyris Software, Qld), a nutrient
analysis program based on Australian food composition
tables. Where possible, Australian data on the vitamin D
content of foods will be used in the analyses [42]. Where
Australian data are unavailable, a vitamin D database that
we have recently compiled from UK, US, and European
food composition tables will be employed.
Sun exposure questionnaire Skin colour, owing to dif-
ferent quantities and compositions of melanin, affects
the cutaneous photochemical synthesis of vitamin D
[43]. Similarly, season and latitude influence vitamin D
production in the body [43]. To take these into account,
we have included a sun exposure questionnaire. Skin
characteristics will be measured by grading hair colour
(ten-point visual scale), eye colour, and reaction to sun
exposure (four-point scale: never to always burn) [44].
Participants will be asked to estimate their average hours
of sun exposure on a usual working day and on a non-
working day, to indicate how often sunscreen was used
and its sun protection factor, and to describe the degree
of clothing worn when outside during the summer and
winter seasons. The description of clothing worn will
then be used to determine the fraction of body surface
area exposed to sunlight [45] and to calculate a sun
index [45]:
Sun index ¼ Hours of sun exposure per week
 Fraction of body surface area exposed
International Physical Activity Questionnaire The
aim of the validated International Physical Activity Ques
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people engage in during their average day [38]. We
opted to include the short version to make it more
timely and convenient for participants, given that its
purpose is to determine any change in physical activity
that could influence our study outcomes. This version
refers to the preceding 7 days and asks participants to
report the number of days, and of hours and minutes,
spent on vigorous activity, such as aerobics, or moderate
activity, such as carrying light loads [38]. It also asks
about the number of days, and of hours and minutes,
participants walked for at least 10 minutes and how
much time they spent sitting for any activity (work,
travel, leisure, and so on) over the preceding 7 days.
Secondary outcome information derived from this
short survey might provide some insight into whether
different activity levels might be correlated with different
vitamin D levels. While it is unlikely that we would
reach any solid conclusions from this particular dataset,
it might serve as a potential starting point for further,
more comprehensive research in future.
Beck’s Depression Inventory Beck’s Depression Inven-
tory (2nd edition) is one of the most commonly used
and validated diagnostic tools for depression and for
determining its severity in diverse population groups,
including different ethnicities and age groups, and in
those with and without histories of depressive disorders
or psychological distress [46, 47]. The influence of vita-
min D deficiency on the likelihood of reporting depres-
sive symptoms is currently unknown [48, 49], thus we
have chosen to employ this questionnaire as a reliable
tool for examining this relationship at baseline, and to
assess whether depressive symptom reporting might
change following vitamin D supplementation.
In this questionnaire, participants will be asked to re-
port the frequency by which they have experienced such
feelings as sadness, discouragement, dissatisfaction, guilt,
indecisiveness, irritation, and suicidal thoughts, over the
past 7 days. There are 21 multiple choice items in total,
each with four possible responses ranging from a score
of 0 to 3 [39, 50]. The scores for all 21 items are tallied
to reach a total score between 0 and 63, with higher
scores indicating more severe levels of depression.
Knee and back pain questionnaire There has been a
fair amount of evidence showing an association be-
tween circulating 25(OH)D concentrations and certain
bone health outcomes, including osteoporosis, rickets,
falls and fractures, and osteoarthritis [51, 52, 30]. How-
ever, research is lacking in relation to vitamin D and
self-reported musculoskeletal pain. As such, we have
added the knee and back pain questionnaire in an at-
tempt to establish whether vitamin D supplementationmight improve scores on self-reported pain scales and
therefore prove useful for the treatment of high-risk in-
dividuals, such as older people and overweight or obese
individuals. This questionnaire will collect information
from participants regarding the amount of pain they
currently experience in their dominant knee during
certain activities, such as walking or standing, the dur-
ation in which they have experienced back pain, and
the intensity of any back pain encountered within the
past 6 months.
Statistical analysis
All analyses will be conducted according to the intention
to treat principle. Baseline patient characteristics will be
assessed using Student’s t test for continuous variables
and the chi-squared test for categorical variables, to
check for any imbalance between the two groups. Distri-
butional assumptions will be checked and continuous
variables will be transformed if normality is violated.
Baseline and within-group differences will be assessed
using paired Student’s t tests for both primary and sec-
ondary outcome measures. The effects of the interven-
tion on the outcomes (between-group differences) at 16
weeks will be analyzed using changes in outcome vari-
ables and linear regression. Here, the variable of interest
at 16 weeks will be the outcome variable minus baseline
variable, which will be additionally adjusted for baseline
values. Using linear regression, pre-specified subgroups,
such as age categories, sex, and body mass index will
be assessed for effect modification on anthropometric,
metabolic, and cardiovascular outcomes.
A separate analysis will be conducted for the severely
vitamin D deficient group, who will undergo a nonran-
domized mandatory treatment with vitamin D supple-
mentation as per protocol. A within-subject analysis on
primary and secondary outcome measures using paired t
tests will be conducted on this group.
All analyses will be performed using Stata statistical
software. All tests will be two-sided and P values of less
than 0.05 will be considered statistically significant.
Discussion
To the best of our knowledge, this is the first clinical
trial supplementing a sufficient dose of vitamin D in
vitamin D deficient individuals, employing gold-standard
measures of insulin sensitivity and secretion, and com-
prehensively investigating mechanisms of action includ-
ing chronic low-grade inflammation in human beings.
Insulin resistance is common in obesity and is a key
pathogenic process underpinning type 2 diabetes. Inter-
ventions that reduce insulin resistance, including lifestyle,
weight loss, and pharmacological therapies, prevent and
treat type 2 diabetes [53]; however, to date they have failed
to slow the increasing burden of insulin resistance and
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fects approximately 1 million Australians and, if it con-
tinues to rise at the current rate, it is estimated that
this number will increase to 3 million by 2025 [31].
Diabetes is a major cause of morbidity and mortality,
primarily due to an increased risk of cardiovascular dis-
ease. Moreover, Australians with type 2 diabetes require
healthcare, carers, and government subsidies totalling
up to 6 billion dollars in healthcare costs annually. It is
vital that additional effective primary prevention strat-
egies are established to reduce insulin resistance and
prevent and manage type 2 diabetes [31]. This trial will
thus inform and advance this important field.
If vitamin D supplementation improves insulin sensi-
tivity or secretion in this trial, then with large-scale
interventions, treating vitamin D deficiency could be-
come a mainstream strategy for diabetes prevention in
overweight and obese individuals who are deficient in
vitamin D. Vitamin D supplementation would offer a
cost-effective and easily administered intervention that
could have a considerable impact on health outcomes
in Australia and worldwide. In addition, vitamin D
could also play a role in counteracting adverse cardio-
vascular events, as well as improving underlying in-
flammatory responses, thereby decreasing risk factors
associated with a range of metabolic conditions. High-
quality clinical trials, such as this, are therefore an im-
portant first step towards elucidating the true poten-
tial of vitamin D supplementation in promoting health
and well-being, and reducing insulin resistance and
potentially the risk of type 2 diabetes and its associ-
ated comorbidities.
Recent meta-analyses of studies examining the effect
of vitamin D on type 2 diabetes and cardiovascular
disease risk factors have produced largely negative re-
sults [23, 26]. Yet, some studies have suggested that im-
provements are only observed in vitamin D deficient
individuals and only with adequate vitamin D supple-
mentation [24, 36, 54]. Nevertheless, few trials have in-
volved vitamin D deficient participants or provided
adequate dosages, highlighting the need for trials that
address these knowledge gaps.
Mechanisms of action of vitamin D might include dir-
ect and indirect effects on both insulin sensitivity and
secretion, which have been investigated largely in animal
and in-vitro studies. Vitamin D was shown to increase
transcriptional activation and expression of the insulin
receptor gene, which facilitates both basal- and insulin-
stimulated glucose oxidation and results in improved
insulin sensitivity [55–57]. Vitamin D also enhances in-
sulin action and signal transduction by regulating extra-
cellular calcium [58]. Vitamin D influences β-cell insulin
secretion by elevating intracellular calcium, which is a
crucial mechanism involved in β-cell glycolysis and thesignaling of circulating glucose [29]. Vitamin D has also
been implicated in the modulation of cytokine mediated
β-cell apoptosis, the most important factor in the devel-
opment and progression of type 2 diabetes [59, 60]. Not-
ably, vitamin D also counteracts the harmful effects of
advanced glycation products, which are essential for the
development of type 2 diabetes complications and have
recently been associated with the development of insulin
resistance [61]. The presence of vitamin D receptors and
vitamin D binding protein in pancreatic islets and nearly
all inflammatory cells supports the idea that vitamin D
plays a crucial role in the function of these cells, and
potentially in the subsequent development of type 2 dia-
betes [62]. However, high-quality randomized trials re-
main scarce, and thus the current clinical trial plans to
address this gap by comprehensively investigating mech-
anisms of vitamin D action in-vivo in human beings.
The mechanism by which vitamin D is believed to
improve cardiac function and reduce the risk of hyper-
tension is primarily via downregulating the renin-
angiotensin-aldosterone system [63–66]. Vitamin D re-
duces levels of angiotensin II in the plasma, thereby re-
ducing angiotensin-II-induced vasoconstriction [63–
65]. Consistent with this notion, those who are defi-
cient in vitamin D were found to have heightened
levels of circulating angiotensin II, thereby increasing
their risk of hypertension [63]. Vitamin D also en-
hances endothelial vasodilatation and modulates the
flux of calcium, leading to reduced secretion of renin
by juxtaglomerular cells present in vascular smooth
muscle tissue, which could explain some of the antihy-
pertensive effects of vitamin D [63–65]. Vitamin D,
through its effects on advanced glycation products and
oxidative stress [67], might also alleviate hypertension
and reduce the risk of cardiovascular disease [68].
Another link between vitamin D and cardiovascular
health is through its direct and indirect effects on lipid
profiles. The indirect mechanism again refers to the
calcium-regulating function of vitamin D, whereby in-
creased calcium levels are proposed to reduce hepatic
triglyceride formation and secretion [20]. It has also
been suggested that vitamin D receptors improve lipid
metabolism by reducing acetylated low-density lipopro-
tein cholesterol uptake [69]. More direct effects include
the promotion of high-density lipoprotein cholesterol
particle formation and the regulation of serum apoli-
poprotein A-1 levels by vitamin D, both of which con-
tribute to increased cholesterol transport and overall
improved lipid profiles [69–71].
Research investigating the role of vitamin D in redu-
cing underlying chronic inflammation has also been
fairly limited. However, preliminary findings suggest
multiple nongenomic actions for vitamin D, alongside
observed alterations in gene and protein expression
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in-vitro investigations have identified the presence of
vitamin D receptors in dendritic cells, monocytes and
activated lymphocytes, among other inflammatory
cells [62]. Moreover, 1,25(OH)D3 applied to isolated
monocytes has been shown to regulate chemokine and
cytokine secretion in patients with type 2 diabetes [72].
This in turn inhibits the pro-inflammatory actions of
monocytes and decreases the proliferation and stimula-
tory abilities of T-cells, both of which are mechanisms
thought to be due to a reduction in the expression of
surface markers including major histocompatibility
complex-II [72]. Where the absence of vitamin D re-
ceptors was observed, there appeared to be an escal-
ation of pro-inflammatory activity by such cytokines as
TNF-α, IL6, and CRP, which is thought to result pri-
marily from an increase in NFκB activity [73, 29]. Sup-
porting this notion, studies have also found that NFκB
translocation appeared to be arrested, and its activity
diminished, by the active form of vitamin D [74–76].
From these limited in-vitro studies stems the current
belief that vitamin D is, at least in part, involved in
regulating the signaling and stimulation of NFκB,
while also controlling both separate and subsequent
cytokine activity. Nevertheless, research in human be-
ings, particularly in clinical trials of vitamin D supple-
mentation or investigating chronic inflammation, are
lacking. This trial can therefore corroborate previous
knowledge, while also providing important explanations
regarding the role of vitamin D in human inflammatory
responses, and subsequent development of disease.
Methodological considerations
The strengths of the current study include the gold-
standard study methodology, employing both randomi-
zation and double-blinding of both participants and
investigators, to limit bias; the placebo-controlled design;
the use of supplementary questionnaires to control for
possible confounders, such as diet, physical activity, sun
exposure, and seasonality; the involvement of vitamin D
deficient participants; the use of an optimal dose of
4,000 IU vitamin D per day for 16 weeks, considered
sufficient to raise plasma 25(OH)D concentrations;
and the use of direct measures of insulin sensitivity
and secretion, such as the oral glucose tolerance test,
intravenous glucose tolerance test, and gold-standard
euglycemic clamp, alongside comprehensive explor-
ation of mechanisms of vitamin D action.
Despite these strengths, there are also potential limi-
tations. First, there might be self-selection bias, given
that recruitment is achieved via voluntary participation
by interested subjects. These subjects might not repre-
sent the entire target population because they might be
characteristically different from the volunteers (that is,potentially more health-conscious). However, randomi
zation should serve as an effective means of minimizing
this risk. Second, because we are only recruiting adults
with a body mass index above 25 kg/m2, but who are
otherwise healthy (nondiabetic, no medication, and so
on), the results of the study would not be generalizable
to other populations, such as those within a healthy
weight range, children, or those with diagnosed dia-
betes or other medical conditions and comorbidities.
Third, our study will only measure surrogate markers,
such as blood pressure, fasting glucose, and insulin sen-
sitivity and insulin secretion. Although these are risk
factors for diabetes and cardiovascular disease, longi-
tudinal follow-up studies would be necessary to ascer-
tain whether a change in these risk factors translates
into decreased incidence of diabetes and cardiovascu-
lar disease.
Finally, the self-report nature of the questionnaire
components of this study might introduce social desir-
ability bias, scale format and anchor biases, or other
construct and formatting related problems [77]. How-
ever, most of the questionnaires selected have been vali-
dated for construct and internal validity, among other
quality indicators. Further, the double-blind design will
ensure any impact from these biases occurs equally in
both groups. The questionnaire data are secondary
outcome measures and will be used to supplement the
objective measurements obtained in the study. Data
from these sources are thus not treated as definitive
findings, nor are they intended to establish any aspects
of causality.
Vitamin D deficiency is now pandemic across most
populations, but with the use of supplements, treatment
can easily be administered on a population-wide level.
Before this can occur, however, randomized trials, such
as the one described here, are necessary, to elucidate the
effect of vitamin D on chronic conditions, including type
2 diabetes and cardiovascular disease. If an effect is
established in our clinical trial, it could serve as a basis
for future research and lead to feasible and cost-effective
strategies to treat vitamin D deficiency and decrease the
risk of type 2 diabetes and cardiovascular disease on a
global scale.Trial status
This randomized trial commenced in July 2014, with
the first eligible participant enrolment taking place on
27 July 2014. The trial is currently ongoing and actively
recruiting, and expected to take approximately 3 years
(from the commencement date to completion).
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